Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

ClinicalTrials.gov ID: NCT06840392

Public ClinicalTrials.gov record NCT06840392. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Double-dummy, Placebo-controlled, Multicenter, Phase 3 Study Assessing the Efficacy, Safety, and Tolerability of 2 Doses of Remibrutinib Over a 68-week Treatment Period in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE-2)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).

Study identification

NCT ID
NCT06840392
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
565 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years to 100 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 19, 2025
Primary completion
Jun 2, 2027
Completion
Oct 20, 2027
Last update posted
Aug 20, 2026

2025 – 2027

United States locations

U.S. sites
35
U.S. states
18
U.S. cities
33
Facility City State ZIP Site status
Total Skin and Beauty Dermatology Center PC Birmingham Alabama 35205
CTT Research Gilbert Arizona 85234
Ctr for Dermatology Clinical Res Fremont California 95438
USC Keck School of Medicine Los Angeles California 90033
MedDerm Associates San Diego California 92103
Driven Research Miami Florida 33126
Floridian Research Institute Miami Florida 33179
Sarasota Arthritis Res Ctr Sarasota Florida 34239
University Of South Florida Tampa Florida 33612
Emory School of Med Dermatology Atlanta Georgia 30303
Atlanta Biomedical Clin Res LLC Atlanta Georgia 30331
Northwestern University Chicago Illinois 60611
Endeavor Health Glenview Illinois 60077
Dundee Dermatology West Dundee Illinois 60118
Southern IN Clinical Trials New Albany Indiana 47150
Beth Israel Deaconess Med Center Boston Massachusetts 02215
Metro Boston Clinical Partners Brighton Massachusetts 02135
Clinical Research Inst of MI Chesterfield Michigan 48047
Deluxe Dermatology St Louis Missouri 63117
Skin Specialists PC Omaha Nebraska 68144
Vivida Dermatology Las Vegas Nevada 89119
North Shore University Hospital New Hyde Park New York 11040
Cameron Dermatology New York New York 10023
Optima Research Boardman Boardman Ohio 44512
Ohio State University Columbus Ohio 43210
Wright State University Fairborn Ohio 45324
Apex Clinical Research Center LLC Mayfield Heights Ohio 44124
Clinical Research Ctr of Carolinas Charleston South Carolina 29407
Goodlettsville Dermatology Research Goodlettsville Tennessee 37072-2301
Accurate Clinical Research Humble Texas 77346
Austin Inst for Clinical Research Pflugerville Texas 78660
Center for Clinical Studies-Lee Webster Texas 77598
Care Access Alexandria Arlington Virginia 22206
Complexions Dermatology Danville Virginia 24541
Forefront Dermatology Vienna Virginia 22182

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 95 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06840392, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 20, 2026 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06840392 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →